Several analogues of somatostatin were examined in the Mia PaCa-2 human pancreatic cancer cell line for their ability to promote tyrosine phosphatase activity affecting the receptors for the epidermal growth factor. The inhibition of growth of the Mia PaCa-2 cells in culture was also evaluated to determine the mechanism of action of somatostatin analogues and their relative effectiveness in inhibiting cancer growth. Of the analogues tested D-Phe-Cys-Tyr-D-Trp-LysVal-Cys-Trp-NH2 (RC-160) caused the greatest stimulation of tyrosine phosphatase activity. Analogue D-Phe-Cys-Tyr-DTrp-Lys-Val-Cys-Thr-NH2 (RC-121) had less effect but was more potent than somatostatin-14. Analogue D-Phe-Cys-Phe-DTrp-Lys-Thr-Cys-Thr(ol) (SMS 201-995) produced no significant dephosphorylation. The analogues displayed the same order of activity in assays on growth inhibition of Mia PaCa-2 cells in cultures. Analogue (SMS-201-995) caused virtually no tyrosine phosphatase stimulation or growth inhibition in this cancer cell line, although it possesses a much higher antisecretory activity than somatostatin-14 in normal tissues. These observations indicate that somatostatin and some of its analogues can act as growth inhibitors in cancer cells through the activation of tyrosine phosphatase. These data reinforce the view that somatostatin analogue RC-160 and related compounds could be used for treatment of pancreatic cancer.
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Somatostatin is a hormone widely distributed in the body, which, in addition to endocrine actions, can also have exocrine and paracrine effects (1) . Somatostatin can exert inhibitory actions on various tissues and affect many cellular functions (1) (2) (3) . Receptors for somatostatin that mediate these actions have been found in normal tissues and in tumors (3) (4) (5) . Two well studied cellular processes affected by somatostatin are secretion and growth (1) (2) (3) (4) (5) . The processes of secretion by many different cells and tissues can be inhibited by somatostatin (2, 3) . Among the effects induced by somatostatin is the inhibition of pancreatic exocrine secretion of protein and bicarbonate and of endocrine events, including the reduction in the release of insulin and glucagon (2, 4) . Somatostatin-14 and its analogues have been used clinically to treat various tumors and other conditions (5) (6) (7) .
Inhibition of tumor growth by somatostatin could occur through the suppression of secretion of various hormones and/or by direct effects on the neoplasm itself. For pancreatic cancers, somatostatin inhibits the release of cholecystokinin, gastrin, and secretin (1-4), which have trophic effects on the growth of the pancreas and, possibly, on pancreatic tumors (5, 8) . The Mia PaCa-2 human undifferentiated pancreatic cancer cell line, developed by Yunis (9) , has been shown to have somatostatin receptors (10) . Somatostatin inhibited epidermal growth factor (EGF)-stimulated growth of Mia PaCa-2 line in cell cultures (11) . This demonstrated that somatostatin could inhibit pancreatic cancer growth not only indirectly through the modulation of circulating hormone levels but also through direct effects.
The somatostatin receptor-somatostatin complex in Mia PaCa-2 cells could act as a specific tyrosine phosphatase (10) , and this activity could be related to the growth-inhibiting effects obtained (11) . The relationship between tyrosine phosphorylation and growth stimulation was suggested by the finding of parallel stimulation of both growth and tyrosine kinase activity by the EGF-EGF receptor complex (12) and the erbB oncogene product (13, 14) . The finding of an independent enzyme acting as a tyrosine phosphatase and a growth inhibitor supports the hypothesis of a functional relationship between phosphorylation and growth (13, (15) (16) (17) , although some observations indicate that phosphorylation and growth may vary independently in some cells (18, 19) . Additional evidence could help to elucidate these phenomena.
An implication of this relationship between tyrosine phosphatase and growth inhibition would be that somatostatin could serve as a therapeutic agent in the treatment of pancreatic cancer and other tumors. However, it is well established that therapeutic use of somatostatin is impractical because of its short half-life in circulation (5) and broad spectrum of activities (1) (2) (3) (4) . To circumvent these problems, analogues of somatostatin with enhanced selectivity and greater stability have been developed (1-7, 20, 21) . One of these is the octapeptide analogue D-Phe-Cys-Phe-D-TrpLys-Thr-Cys-Thr(ol) (SMS-201-995) of Bauer et al. (20) . This analogue has been demonstrated to be an effective antisecretory agent with proven clinical effectiveness in acromegaly, endocrine tumors of the gut and pancreas, and other conditions by Schally and coworkers (3, 5, 21) , have also been found to be highly active, long-acting, and endowed with significant antitumor activity after in vivo administration (5, 22, 23) . In the studies reported herein, we examined the ability of these somatostatin analogues to directly inhibit the growth of Mia PaCa-2 cells in cultures and to stimulate the tyrosine phosphatase activity of somatostatin receptors in this cell line.
MATERIALS AND METHODS
Peptides. The tetradecapeptide somatostatin-14 (Ala-GlyCys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys-OH) tTo whom reprint requests should be sent.
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. (21) . These analogues also possessed antitumor activity in vivo on prostate and pancreatic cancers (22, 23) and caused a powerful inhibition of exocrine and endocrine pancreatic secretion (4) . Analogue D-Phe-Cy's-Phe-DTrp-Lys-Thr-Cys-Thr-(ol) (7, 20) containing a C-terminal amino alcohol was obtained from Sandoz Pharmaceutical. All the three cyclic octapeptide analogs share some common amino acid sequences (3) (4) (5) 21 Phosphatase Assay. Phosphatase assays were performed as described (10) . Mia PaCa-2 cell membranes from cells grown to confluence, scraped mechanically from the Petri dish, and isolated by homogenization and by differential centrifugation (12) were prelabeled with [y-32P]ATP (20 aM) in the presence of 10 ,uM EGF at 0°C for 60 min in 20 mM Hepes buffer (pH 7.5) containing 2.0 mM MnCl2. Cell membranes were incubated in the presence of an excess of unlabeled ATP (0.8 mM) at 0°C for 60 min in the presence or absence of somatostatin or one of the three analogues at concentrations from 10-11 M to 10-6 M (10). EGF receptor was purified by SDS gradient gel electrophoresis, and radioactivity in the 170-kDa band was measured (10) . The A similar spectrum of activity among somatostatin analogues on growth inhibition and stimulation of tyrosine phosphatase of EGF receptors supports the hypothesis that these two phenomena are causally related. The relationship between phosphorylation of tyrosine residues of proteins and growth control has been suggested by Ushiro and Cohen (25) . Additional evidence for this relationship comes from the similar tyrosine kinase activity of erbB and EGF receptors (14, 26 (16) .
Our evidence that somatostatin and its analogues can activate an independent specific tyrosine phosphatase (10) and inhibit growth (11) through a mechanism independent of the EGF receptor-tyrosine kinase system supports the hypothesis that these phenomena are functionally linked. Our findings that somatostatin analogues affect these two processes to a similar extent further support the hypotheses of a functional relationship. Other studies suggesting the existence of two EGF receptors (27) , or of two forms of the EGF receptor (17), may provide another explanation for the discrepancies noted by some investigators between the processes of phosphorylation and growth (18, 19) . The complexity of the message transduction process itself may also help explain these discrepancies. Yu and Czech (16) envision the multistep process of insulin message transduction as an initial autophosphorylation of the ,3 subunit of the insulin receptor, followed by its activation of tyrosine kinase phosphorylation of the P160 protein, and finally by the phosphorylation and activation of a serine kinase by this phosphorylated P160 protein. This model is analogous to that shown in Figs. 3 and 4 for phosphotyrosine kinase activities of EGF receptor and erbB. Two separate tyrosine phosphorylation events occur in this system, (i) the autophosphorylation of EGF receptor and erbB and (ii) the phosphorylation of an acceptor protein, for instance P160 in the insulin system. It is suggested in Fig. 4 that the phosphorylation of the tyrosine kinase (either the EGF receptor or the erbB) provides a phosphate to be transferred to the acceptor protein. This is conjectural, because it is possible that the phosphorylation event on the receptor (or oncogene) merely activates the protein. However, it is an attractive hypothesis to equate these phosphorylation reactions with the reduction of the energy of activation of the enzymatic phosphorylation event. Because multiple steps involving phosphorylation at tyrosine residues are implicated in the cascade of growth regulation and because somatostatin can promote dephosphorylation at more than one of these steps (10), somatostatin may influence a variety of cells in different ways depending on which phosphorylated protein is most affected in each cell (5, 17, 27) . Even though the analogue SMS 201-995 has been proven to be a powerful inhibitor of pancreatic secretions (4), in our studies in the in vitro model, it lacked the ability to directly inhibit pancreatic cancer cell growth. Our data also indicate that the somatostatin receptor in Mia PaCa-2 pancreatic cancer cells involved in stimulating dephosphorylation of endogenous phosphorylated EGF receptor recognizes the endogenous tetradecapeptide somatostatin and two of its octapeptide analogues, RC-160 and RC-121, but not the (17, 27 
